March 2012 in “Journal of The American Academy of Dermatology” Latisse is safe and effective for long-term eyelash growth in people with thin eyelashes from chemotherapy or unknown causes.
38 citations
,
October 2014 in “British journal of dermatology/British journal of dermatology, Supplement” The study found that daily use of bimatoprost ophthalmic solution 0.03% for one year was effective in improving eyelash growth and patient satisfaction in both idiopathic and chemotherapy-induced hypotrichosis, with no serious drug-related adverse events reported.
23 citations
,
April 2010 in “Clinical, cosmetic and investigational dermatology” This review discusses the cutaneous application of bimatoprost ophthalmic solution 0.03% for enhancing upper eyelash growth and suggests it is both safe and effective; no new clinical results are reported.
March 2025 in “JAAD reviews.” This review found that bimatoprost effectively treats chemotherapy-induced eyelash loss, known as milphosis, in cancer patients, as demonstrated in three small trials, but further research is needed due to limitations like small sample sizes and short follow-up periods.
12 citations
,
September 2012 in “Plastic and Reconstructive Surgery” This study found that combining follicular isolation with de-epithelialization in eyebrow and eyelash transplantation led to better outcomes and fewer complications than using follicular isolation alone.
